You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameQuetiapine
Accession NumberDB01224  (APRD00675)
TypeSmall Molecule
GroupsApproved
DescriptionQuetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.
Structure
Thumb
Synonyms
2-[2-(4-Dibenzo[b,F][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol
Quetiapina
Quetiapine
Quetiapine fumarate
Quetiapine hemifumarate
Quetiapinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-quetiapinetablet (immediate release)25 mgoralBgp Pharma Ulc2014-06-092015-12-31Canada
Abbott-quetiapinetablet (immediate release)100 mgoralBgp Pharma Ulc2014-06-092015-12-31Canada
Abbott-quetiapinetablet (immediate release)200 mgoralBgp Pharma Ulc2014-06-132015-12-31Canada
Abbott-quetiapinetablet (immediate release)300 mgoralBgp Pharma Ulc2014-06-092015-12-31Canada
Accel-quetiapinetablet200 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-quetiapinetablet25 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-quetiapinetablet300 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-quetiapinetablet100 mgoralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-quetiapinetablet150 mgoralAccel Pharma Inc2015-03-03Not applicableCanada
Ach-quetiapine Fumarate XRtablet (extended-release)200 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-quetiapine Fumarate XRtablet (extended-release)400 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-quetiapine Fumarate XRtablet (extended-release)300 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-quetiapine Fumarate XRtablet (extended-release)50 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-quetiapine Fumarate XRtablet (extended-release)150 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Act Quetiapinetablet300 mgoralActavis Pharma Company2008-09-04Not applicableCanada
Act Quetiapinetablet150 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Act Quetiapinetablet25 mgoralActavis Pharma Company2008-09-04Not applicableCanada
Act Quetiapinetablet100 mgoralActavis Pharma Company2008-09-04Not applicableCanada
Act Quetiapinetablet200 mgoralActavis Pharma Company2008-09-04Not applicableCanada
Auro-quetiapinetablet200 mgoralAuro Pharma Inc2012-10-18Not applicableCanada
Auro-quetiapinetablet300 mgoralAuro Pharma Inc2012-10-18Not applicableCanada
Auro-quetiapinetablet25 mgoralAuro Pharma Inc2012-10-18Not applicableCanada
Auro-quetiapinetablet150 mgoralAuro Pharma IncNot applicableNot applicableCanada
Auro-quetiapinetablet100 mgoralAuro Pharma Inc2012-10-18Not applicableCanada
Ava-quetiapinetablet100 mgoralAvanstra Inc2011-11-282014-08-21Canada
Ava-quetiapinetablet200 mgoralAvanstra Inc2011-11-282014-08-21Canada
Ava-quetiapinetablet25 mgoralAvanstra Inc2011-11-282014-08-21Canada
Bio-quetiapinetablet100 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-quetiapinetablet150 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-quetiapinetablet300 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-quetiapinetablet200 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-quetiapinetablet25 mgoralBiomed PharmaNot applicableNot applicableCanada
Dom-quetiapinetablet200 mgoralDominion Pharmacal2010-05-01Not applicableCanada
Dom-quetiapinetablet300 mgoralDominion Pharmacal2010-07-01Not applicableCanada
Dom-quetiapinetablet25 mgoralDominion Pharmacal2010-05-01Not applicableCanada
Dom-quetiapinetablet150 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-quetiapinetablet100 mgoralDominion Pharmacal2010-06-01Not applicableCanada
Ipg-quetiapinetablet (immediate release)100 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-quetiapinetablet (immediate release)200 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-quetiapinetablet (immediate release)300 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-quetiapinetablet (immediate release)25 mgoralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Jamp-quetiapinetablet200 mgoralJamp Pharma Corporation2010-04-02Not applicableCanada
Jamp-quetiapinetablet300 mgoralJamp Pharma Corporation2010-06-18Not applicableCanada
Jamp-quetiapinetablet150 mgoralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-quetiapinetablet25 mgoralJamp Pharma Corporation2010-04-02Not applicableCanada
Jamp-quetiapinetablet100 mgoralJamp Pharma Corporation2010-04-02Not applicableCanada
Mar-quetiapinetablet (immediate release)25 mgoralMarcan Pharmaceuticals Inc2014-01-16Not applicableCanada
Mar-quetiapinetablet (immediate release)100 mgoralMarcan Pharmaceuticals Inc2014-01-16Not applicableCanada
Mar-quetiapinetablet (immediate release)200 mgoralMarcan Pharmaceuticals Inc2014-01-16Not applicableCanada
Mar-quetiapinetablet (immediate release)300 mgoralMarcan Pharmaceuticals Inc2014-01-16Not applicableCanada
Mint-quetiapinetablet25 mgoralMint Pharmaceuticals Inc2015-03-19Not applicableCanada
Mint-quetiapinetablet150 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-quetiapinetablet100 mgoralMint Pharmaceuticals Inc2015-03-19Not applicableCanada
Mint-quetiapinetablet200 mgoralMint Pharmaceuticals Inc2015-03-19Not applicableCanada
Mint-quetiapinetablet300 mgoralMint Pharmaceuticals Inc2015-03-19Not applicableCanada
Mylan-quetiapinetablet100 mgoralMylan Pharmaceuticals Ulc2008-09-04Not applicableCanada
Mylan-quetiapinetablet200 mgoralMylan Pharmaceuticals Ulc2008-09-04Not applicableCanada
Mylan-quetiapinetablet300 mgoralMylan Pharmaceuticals Ulc2008-09-04Not applicableCanada
Mylan-quetiapinetablet25 mgoralMylan Pharmaceuticals Ulc2008-09-04Not applicableCanada
Nat-quetiapinetablet200 mgoralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-quetiapinetablet25 mgoralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-quetiapinetablet300 mgoralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-quetiapinetablet100 mgoralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-quetiapinetablet150 mgoralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nu-quetiapinetablet300 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-quetiapinetablet25 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-quetiapinetablet100 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-quetiapinetablet200 mgoralNu Pharm IncNot applicableNot applicableCanada
PHL-quetiapinetablet200 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-quetiapinetablet300 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-quetiapinetablet25 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-quetiapinetablet100 mgoralPharmel Inc2010-02-18Not applicableCanada
PMS-quetiapinetablet300 mgoralPharmascience Inc2008-09-04Not applicableCanada
PMS-quetiapinetablet25 mgoralPharmascience Inc2008-09-04Not applicableCanada
PMS-quetiapinetablet100 mgoralPharmascience Inc2008-09-04Not applicableCanada
PMS-quetiapinetablet50 mgoralPharmascience Inc2011-01-21Not applicableCanada
PMS-quetiapinetablet200 mgoralPharmascience Inc2008-09-04Not applicableCanada
PMS-quetiapinetablet150 mgoralPharmascience IncNot applicableNot applicableCanada
Priva-quetiapinetablet150 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-quetiapinetablet200 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-quetiapinetablet300 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-quetiapinetablet25 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-quetiapinetablet100 mgoralPharmapar IncNot applicableNot applicableCanada
Pro-quetiapinetablet100 mgoralPro Doc Limitee2008-10-23Not applicableCanada
Pro-quetiapinetablet200 mgoralPro Doc Limitee2008-10-23Not applicableCanada
Pro-quetiapinetablet300 mgoralPro Doc Limitee2008-10-23Not applicableCanada
Pro-quetiapinetablet25 mgoralPro Doc Limitee2008-10-23Not applicableCanada
Quetiapinetablet200 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Quetiapinetablet300 mgoralSanis Health Inc2010-07-26Not applicableCanada
Quetiapinetablet300 mgoralSivem Pharmaceuticals Ulc2009-02-26Not applicableCanada
Quetiapinetablet25 mgoralSanis Health Inc2010-07-26Not applicableCanada
Quetiapinetablet25 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Quetiapinetablet25 mgoralSivem Pharmaceuticals Ulc2009-02-26Not applicableCanada
Quetiapinetablet300 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Quetiapinetablet100 mgoralSanis Health Inc2010-07-26Not applicableCanada
Quetiapinetablet100 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Quetiapinetablet100 mgoralSivem Pharmaceuticals Ulc2009-02-26Not applicableCanada
Quetiapinetablet200 mgoralSanis Health Inc2010-07-26Not applicableCanada
Quetiapinetablet150 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Quetiapinetablet200 mgoralSivem Pharmaceuticals Ulc2009-02-26Not applicableCanada
Quetiapine Tabletstablet200 mgoralAccord Healthcare Inc2012-06-20Not applicableCanada
Quetiapine Tabletstablet300 mgoralAccord Healthcare Inc2012-06-20Not applicableCanada
Quetiapine Tabletstablet25 mgoralAccord Healthcare Inc2012-06-20Not applicableCanada
Quetiapine Tabletstablet100 mgoralAccord Healthcare Inc2012-06-20Not applicableCanada
Quetiapine Tabletstablet150 mgoralAccord Healthcare Inc2012-06-20Not applicableCanada
Quetiapine XRtablet (extended-release)150 mgoralSivem Pharmaceuticals Ulc2014-01-16Not applicableCanada
Quetiapine XRtablet (extended-release)200 mgoralSivem Pharmaceuticals Ulc2014-01-16Not applicableCanada
Quetiapine XRtablet (extended-release)150 mgoralPro Doc Limitee2014-01-09Not applicableCanada
Quetiapine XRtablet (extended-release)50 mgoralPro Doc Limitee2014-01-09Not applicableCanada
Quetiapine XRtablet (extended-release)300 mgoralSivem Pharmaceuticals Ulc2014-01-16Not applicableCanada
Quetiapine XRtablet (extended-release)200 mgoralPro Doc Limitee2014-01-09Not applicableCanada
Quetiapine XRtablet (extended-release)300 mgoralPro Doc Limitee2014-01-09Not applicableCanada
Quetiapine XRtablet (extended-release)400 mgoralSivem Pharmaceuticals Ulc2014-01-16Not applicableCanada
Quetiapine XRtablet (extended-release)400 mgoralPro Doc Limitee2014-01-09Not applicableCanada
Quetiapine XRtablet (extended-release)50 mgoralSivem Pharmaceuticals Ulc2014-01-01Not applicableCanada
Ran-quetiapinetablet25 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Ran-quetiapinetablet100 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Ran-quetiapinetablet200 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Ran-quetiapinetablet300 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Ratio-quetiapinetablet100 mgoralRatiopharm Inc Division Of Teva Canada Limited2008-08-272014-09-19Canada
Ratio-quetiapinetablet200 mgoralRatiopharm Inc Division Of Teva Canada Limited2008-08-272014-09-19Canada
Ratio-quetiapinetablet300 mgoralRatiopharm Inc Division Of Teva Canada Limited2008-08-272014-09-19Canada
Ratio-quetiapinetablet25 mgoralRatiopharm Inc Division Of Teva Canada Limited2008-08-222014-09-19Canada
Riva-quetiapinetablet100 mgoralLaboratoire Riva Inc2008-09-24Not applicableCanada
Riva-quetiapinetablet200 mgoralLaboratoire Riva Inc2008-09-24Not applicableCanada
Riva-quetiapinetablet300 mgoralLaboratoire Riva Inc2008-09-24Not applicableCanada
Riva-quetiapinetablet150 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-quetiapinetablet25 mgoralLaboratoire Riva Inc2008-09-24Not applicableCanada
Sandoz Quetiapinetablet100 mgoralSandoz Canada Incorporated2008-09-04Not applicableCanada
Sandoz Quetiapinetablet200 mgoralSandoz Canada Incorporated2008-09-04Not applicableCanada
Sandoz Quetiapinetablet300 mgoralSandoz Canada Incorporated2008-09-04Not applicableCanada
Sandoz Quetiapinetablet25 mgoralSandoz Canada Incorporated2008-09-04Not applicableCanada
Sandoz Quetiapine XRtablet (extended-release)200 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Quetiapine XRtablet (extended-release)50 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Quetiapine XRtablet (extended-release)300 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Quetiapine XRtablet (extended-release)400 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Quetiapine XRtablet (extended-release)150 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Quetiapine Xrttablet (extended-release)50 mgoralSandoz Canada Incorporated2013-06-14Not applicableCanada
Sandoz Quetiapine Xrttablet (extended-release)150 mgoralSandoz Canada Incorporated2013-06-14Not applicableCanada
Sandoz Quetiapine Xrttablet (extended-release)200 mgoralSandoz Canada Incorporated2013-06-14Not applicableCanada
Sandoz Quetiapine Xrttablet (extended-release)300 mgoralSandoz Canada Incorporated2013-06-14Not applicableCanada
Sandoz Quetiapine Xrttablet (extended-release)400 mgoralSandoz Canada Incorporated2013-06-14Not applicableCanada
Seroqueltablet, film coated50 mg/1oralREMEDYREPACK INC.2013-05-142016-03-11Us
Seroqueltablet, film coated100 mg/1oralCardinal Health2010-06-01Not applicableUs
Seroqueltablet, film coated100 mg/1oralAstra Zeneca Pharmaceuticals Lp1997-10-01Not applicableUs
Seroqueltablet, film coated50 mg/1oralRebel Distributors Corp2010-06-01Not applicableUs
Seroqueltablet, film coated200 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-07-08Not applicableUs
Seroqueltablet, film coated200 mg/1oralbryant ranch prepack1997-10-01Not applicableUs
Seroqueltablet, film coated200 mg/1oralContract Pharmacy Services Pa2010-06-01Not applicableUs
Seroqueltablet, extended release150 mg/1oralREMEDYREPACK INC.2011-03-23Not applicableUs
Seroqueltablet, film coated200 mg/1oralPd Rx Pharmaceuticals, Inc.1997-10-01Not applicableUs
Seroqueltablet, film coated50 mg/1oralPhysicians Total Care, Inc.2006-04-28Not applicableUs
Seroqueltablet, film coated50 mg/1oralAstra Zeneca Pharmaceuticals Lp2006-02-13Not applicableUs
Seroqueltablet, film coated200 mg/1oralREMEDYREPACK INC.2013-04-102016-04-05Us
Seroqueltablet, film coated25 mg/1oralREMEDYREPACK INC.2013-05-092016-04-05Us
Seroqueltablet, film coated200 mg/1oralCardinal Health2010-06-01Not applicableUs
Seroqueltablet, film coated25 mg/1oralContract Pharmacy Services Pa2010-06-01Not applicableUs
Seroqueltablet, film coated200 mg/1oralAstra Zeneca Pharmaceuticals Lp1997-10-01Not applicableUs
Seroqueltablet, film coated100 mg/1oralRebel Distributors Corp2010-06-01Not applicableUs
Seroqueltablet, film coated100 mg/1oralPhysicians Total Care, Inc.2006-04-28Not applicableUs
Seroqueltablet, film coated300 mg/1oralbryant ranch prepack2000-11-13Not applicableUs
Seroqueltablet, film coated25 mg/1oralPd Rx Pharmaceuticals, Inc.2011-07-19Not applicableUs
Seroqueltablet, film coated300 mg/1oralContract Pharmacy Services Pa2010-06-01Not applicableUs
Seroqueltablet, film coated100 mg/1oralSTAT Rx USA LLC2011-05-26Not applicableUs
Seroqueltablet, film coated50 mg/1oralREMEDYREPACK INC.2013-05-09Not applicableUs
Seroqueltablet, film coated400 mg/1oralAstra Zeneca Pharmaceuticals Lp2006-02-13Not applicableUs
Seroqueltablet, film coated300 mg/1oralREMEDYREPACK INC.2013-04-102016-03-11Us
Seroqueltablet, film coated50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-16Not applicableUs
Seroqueltablet, film coated300 mg/1oralCardinal Health2010-06-01Not applicableUs
Seroqueltablet, film coated50 mg/1oralContract Pharmacy Services Pa2010-06-01Not applicableUs
Seroqueltablet, film coated300 mg/1oralAstra Zeneca Pharmaceuticals Lp2000-11-13Not applicableUs
Seroqueltablet, film coated200 mg/1oralRebel Distributors Corp2010-06-01Not applicableUs
Seroqueltablet, film coated25 mg/1oralPhysicians Total Care, Inc.2003-11-19Not applicableUs
Seroqueltablet, film coated50 mg/1oralbryant ranch prepack2006-02-13Not applicableUs
Seroqueltablet, film coated100 mg/1oralbryant ranch prepack1997-10-01Not applicableUs
Seroqueltablet, film coated400 mg/1oralContract Pharmacy Services Pa2010-06-01Not applicableUs
Seroqueltablet, film coated400 mg/1oralSTAT Rx USA LLC2011-05-26Not applicableUs
Seroqueltablet, film coated100 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-16Not applicableUs
Seroqueltablet, film coated25 mg/1oralCardinal Health2010-06-01Not applicableUs
Seroqueltablet, film coated400 mg/1oralREMEDYREPACK INC.2013-04-102016-03-11Us
Seroqueltablet, film coated300 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-07-07Not applicableUs
Seroqueltablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.2011-11-18Not applicableUs
Seroqueltablet, film coated100 mg/1oralContract Pharmacy Services Pa2010-06-01Not applicableUs
Seroqueltablet, film coated25 mg/1oralAstra Zeneca Pharmaceuticals Lp2003-06-30Not applicableUs
Seroqueltablet, film coated100 mg/1oralREMEDYREPACK INC.2013-04-242016-03-04Us
Seroqueltablet, film coated300 mg/1oralPhysicians Total Care, Inc.2011-11-18Not applicableUs
Seroqueltablet, film coated25 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-16Not applicableUs
Seroqueltablet, film coated25 mg/1oralbryant ranch prepack2003-06-30Not applicableUs
Seroqueltablet, film coated25 mg/1oralRebel Distributors Corp2010-06-01Not applicableUs
Seroquel 150 mgtablet150 mgoralAstrazeneca Canada Inc2001-01-102006-03-03Canada
Seroquel 300 mgtablet300 mgoralAstrazeneca Canada Inc2001-08-21Not applicableCanada
Seroquel Tab 100mgtablet100 mgoralAstrazeneca Canada Inc1997-12-10Not applicableCanada
Seroquel Tab 200mgtablet200 mgoralAstrazeneca Canada Inc1997-12-10Not applicableCanada
Seroquel Tab 25mgtablet25 mgoralAstrazeneca Canada Inc1997-12-10Not applicableCanada
Seroquel XRtablet (extended-release)150 mgoralAstrazeneca Canada Inc2009-04-14Not applicableCanada
Seroquel XRtablet, extended release400 mg/1oralTYA Pharmaceuticals2007-07-16Not applicableUs
Seroquel XRtablet, extended release150 mg/1oralAstra Zeneca Pharmaceuticals Lp2009-02-01Not applicableUs
Seroquel XRkitAstra Zeneca Pharmaceuticals Lp2014-10-02Not applicableUs
Seroquel XRtablet, extended release150 mg/1oralTYA Pharmaceuticals2009-02-01Not applicableUs
Seroquel XRtablet (extended-release)300 mgoralAstrazeneca Canada Inc2007-09-27Not applicableCanada
Seroquel XRtablet, extended release200 mg/1oralAstra Zeneca Pharmaceuticals Lp2007-07-16Not applicableUs
Seroquel XRtablet, extended release50 mg/1oralPhysicians Total Care, Inc.2011-11-17Not applicableUs
Seroquel XRtablet, extended release200 mg/1oralTYA Pharmaceuticals2007-07-16Not applicableUs
Seroquel XRtablet (extended-release)400 mgoralAstrazeneca Canada Inc2007-09-27Not applicableCanada
Seroquel XRtablet, extended release300 mg/1oralAstra Zeneca Pharmaceuticals Lp2007-07-16Not applicableUs
Seroquel XRtablet (extended-release)50 mgoralAstrazeneca Canada Inc2007-09-27Not applicableCanada
Seroquel XRtablet, extended release300 mg/1oralTYA Pharmaceuticals2007-07-16Not applicableUs
Seroquel XRtablet, extended release50 mg/1oralAstra Zeneca Pharmaceuticals Lp2009-02-01Not applicableUs
Seroquel XRtablet, extended release400 mg/1oralAstra Zeneca Pharmaceuticals Lp2007-07-16Not applicableUs
Seroquel XRtablet (extended-release)200 mgoralAstrazeneca Canada Inc2007-09-27Not applicableCanada
Seroquel XRtablet, extended release50 mg/1oralTYA Pharmaceuticals2009-02-01Not applicableUs
Teva-quetiapinetablet300 mgoralTeva Canada Limited2008-09-04Not applicableCanada
Teva-quetiapinetablet100 mgoralTeva Canada Limited2008-09-04Not applicableCanada
Teva-quetiapinetablet150 mgoralTeva Canada Limited2008-09-04Not applicableCanada
Teva-quetiapinetablet200 mgoralTeva Canada Limited2008-09-04Not applicableCanada
Teva-quetiapinetablet25 mgoralTeva Canada Limited2008-09-04Not applicableCanada
Teva-quetiapine XRtablet (extended-release)150 mgoralTeva Canada Limited2013-03-08Not applicableCanada
Teva-quetiapine XRtablet (extended-release)200 mgoralTeva Canada Limited2013-03-08Not applicableCanada
Teva-quetiapine XRtablet (extended-release)300 mgoralTeva Canada Limited2013-03-08Not applicableCanada
Teva-quetiapine XRtablet (extended-release)50 mgoralTeva Canada Limited2013-03-08Not applicableCanada
Teva-quetiapine XRtablet (extended-release)400 mgoralTeva Canada Limited2013-03-08Not applicableCanada
Torrent-quetiapine Fumaratetablet (immediate release)200 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-quetiapine Fumaratetablet (immediate release)300 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-quetiapine Fumaratetablet (immediate release)25 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-quetiapine Fumaratetablet (immediate release)100 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Van-quetiapinetablet25 mgoralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Van-quetiapinetablet100 mgoralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Van-quetiapinetablet200 mgoralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Van-quetiapinetablet300 mgoralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-quetiapinetablet100 mgoralApotex Inc2008-09-04Not applicableCanada
Apo-quetiapinetablet200 mgoralApotex Inc2008-09-04Not applicableCanada
Apo-quetiapinetablet300 mgoralApotex Inc2008-09-04Not applicableCanada
Apo-quetiapinetablet25 mgoralApotex Inc2008-09-04Not applicableCanada
Quetiapine Fumaratetablet200 mg/1oralSandoz Inc2013-04-05Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralSafecor Health, LLC2014-09-30Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralBreckenridge Pharmaceutical, Inc2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralPhysicians Total Care, Inc.2012-04-02Not applicableUs
Quetiapine Fumaratetablet25 mg/1oralCardinal Health2013-03-01Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralNorth Star Rx Llc2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralCitron Pharma LLC2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralAccord Healthcare Inc.2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralApotex Corp.2012-03-27Not applicableUs
Quetiapine Fumaratetablet100 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralREMEDYREPACK INC.2015-05-26Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralbryant ranch prepack2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralAurobindo Pharma Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet25 mg/1oralLupin Pharmaceuticals, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralGolden State Medical Supply, Inc.2015-07-21Not applicableUs
Quetiapine Fumaratetablet300 mg/1oralLUPIN LIMITED2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralTeva Pharmaceuticals USA Inc2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralREMEDYREPACK INC.2016-01-29Not applicableUs
Quetiapine Fumaratetablet25 mg/1oralRoxane Laboratories, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralMc Kesson Contract Packaging2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralAlembic Pharmaceuticals Limited2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralREMEDYREPACK INC.2013-02-08Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralREMEDYREPACK INC.2013-05-29Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralDr.Reddy's Laboratories Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralMajor Pharmaceuticals2014-06-16Not applicableUs
Quetiapine Fumaratetablet300 mg/1oralCardinal Health2013-03-01Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralNorthstar Rx LLC2015-01-12Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralGolden State Medical Supply, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralAv Kare, Inc.2014-01-17Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralApotex Corp.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralDIRECT RX2015-01-01Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralTYA Pharmaceuticals2012-03-26Not applicableUs
Quetiapine Fumaratetablet100 mg/1oralAscend Laboratories, LLC2013-03-01Not applicableUs
Quetiapine Fumaratetablet25 mg/1oralAvera Mc Kennan Hospital2015-03-09Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralClinical Solutions Wholesale2012-03-28Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralAv Kare, Inc.2014-01-17Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralApotex Corp.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralAlembic Pharmaceuticals Limited2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralREMEDYREPACK INC.2015-08-31Not applicableUs
Quetiapine Fumaratetablet200 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2013-04-05Not applicableUs
Quetiapine Fumaratetablet200 mg/1oralAscend Laboratories, LLC2013-03-01Not applicableUs
Quetiapine Fumaratetablet300 mg/1oralLupin Pharmaceuticals, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet200 mg/1oralBlue Point Laboratories2013-02-28Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralTeva Pharmaceuticals USA Inc2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralMajor Pharmaceuticals2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralREMEDYREPACK INC.2013-02-18Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralREMEDYREPACK INC.2013-03-28Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralPhysicians Total Care, Inc.2012-04-12Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralCardinal Health2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralNorth Star Rx Llc2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralCardinal Health2012-04-02Not applicableUs
Quetiapine Fumaratetablet200 mg/1oralTorrent Pharmaceuticals Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralCitron Pharma LLC2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralAccord Healthcare Inc.2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralGolden State Medical Supply, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine Fumaratetablet100 mg/1oralREMEDYREPACK INC.2014-10-13Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralProficient Rx LP2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralAurobindo Pharma Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralAmerican Health Packaging2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralGolden State Medical Supply, Inc.2015-07-21Not applicableUs
Quetiapine Fumaratetablet50 mg/1oralLUPIN LIMITED2012-03-27Not applicableUs
Quetiapine Fumaratetablet50 mg/1oralRoxane Laboratories, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet25 mg/1oralSandoz Inc2013-04-05Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralSun Pharma Global FZE2012-03-28Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralBreckenridge Pharmaceutical, Inc2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralREMEDYREPACK INC.2014-05-28Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralGolden State Medical Supply, Inc.2015-07-21Not applicableUs
Quetiapine Fumaratetablet400 mg/1oralLUPIN LIMITED2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralTeva Pharmaceuticals USA Inc2012-03-27Not applicableUs
Quetiapine Fumaratetablet300 mg/1oralSandoz Inc2013-04-05Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralREMEDYREPACK INC.2013-02-07Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralBreckenridge Pharmaceutical, Inc2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralPhysicians Total Care, Inc.2012-04-02Not applicableUs
Quetiapine Fumaratetablet100 mg/1oralCardinal Health2013-03-01Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralNorth Star Rx Llc2012-03-27Not applicableUs
Quetiapine Fumaratetablet200 mg/1oralClinical Solutions Wholesale, Llc2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralAccord Healthcare Inc.2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralApotex Corp.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralREMEDYREPACK INC.2015-06-29Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralbryant ranch prepack2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralAurobindo Pharma Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet50 mg/1oralLupin Pharmaceuticals, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralAmerican Health Packaging2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralAvera Mc Kennan Hospital2015-04-16Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralREMEDYREPACK INC.2016-01-29Not applicableUs
Quetiapine Fumaratetablet100 mg/1oralRoxane Laboratories, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralSun Pharma Global FZE2012-03-28Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralREMEDYREPACK INC.2013-02-08Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralREMEDYREPACK INC.2013-05-292016-04-05Us
Quetiapine Fumaratetablet, film coated300 mg/1oralDr.Reddy's Laboratories Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet25 mg/1oralTorrent Pharmaceuticals Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet400 mg/1oralCardinal Health2013-03-01Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralNorthstar Rx LLC2015-01-12Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralGolden State Medical Supply, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralSTAT Rx USA LLC2012-03-26Not applicableUs
Quetiapine Fumaratetablet200 mg/1oralREMEDYREPACK INC.2014-10-08Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralDIRECT RX2015-01-01Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralTYA Pharmaceuticals2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralDr.Reddy's Laboratories Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralCardinal Health2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralNorth Star Rx Llc2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralClinical Solutions Wholesale2012-03-28Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralAv Kare, Inc.2014-01-17Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralApotex Corp.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralAlembic Pharmaceuticals Limited2012-03-26Not applicableUs
Quetiapine Fumaratetablet50 mg/1oralREMEDYREPACK INC.2015-10-27Not applicableUs
Quetiapine Fumaratetablet300 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2013-04-05Not applicableUs
Quetiapine Fumaratetablet300 mg/1oralAscend Laboratories, LLC2013-03-01Not applicableUs
Quetiapine Fumaratetablet400 mg/1oralLupin Pharmaceuticals, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet300 mg/1oralBlue Point Laboratories2013-02-28Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralMajor Pharmaceuticals2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralREMEDYREPACK INC.2013-02-15Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralREMEDYREPACK INC.2013-02-09Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralBreckenridge Pharmaceutical, Inc2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralREMEDYREPACK INC.2014-05-282016-04-05Us
Quetiapine Fumaratetablet, film coated100 mg/1oralCardinal Health2012-04-02Not applicableUs
Quetiapine Fumaratetablet300 mg/1oralTorrent Pharmaceuticals Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralCitron Pharma LLC2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralAccord Healthcare Inc.2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralGolden State Medical Supply, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet25 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine Fumaratetablet100 mg/1oralREMEDYREPACK INC.2015-02-16Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralbryant ranch prepack2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated150 mg/1oralAurobindo Pharma Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralAmerican Health Packaging2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralGolden State Medical Supply, Inc.2015-07-21Not applicableUs
Quetiapine Fumaratetablet100 mg/1oralLUPIN LIMITED2012-03-27Not applicableUs
Quetiapine Fumaratetablet400 mg/1oralRoxane Laboratories, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet100 mg/1oralSandoz Inc2013-04-05Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralSun Pharma Global FZE2012-03-28Not applicableUs
Quetiapine Fumaratetablet25 mg/1oralAscend Laboratories, LLC2013-03-01Not applicableUs
Quetiapine Fumaratetablet100 mg/1oralLupin Pharmaceuticals, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralGolden State Medical Supply, Inc.2015-07-21Not applicableUs
Quetiapine Fumaratetablet50 mg/1oralBlue Point Laboratories2013-02-28Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralTeva Pharmaceuticals USA Inc2012-03-27Not applicableUs
Quetiapine Fumaratetablet400 mg/1oralSandoz Inc2013-04-05Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralREMEDYREPACK INC.2013-02-07Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralBreckenridge Pharmaceutical, Inc2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralPhysicians Total Care, Inc.2012-04-02Not applicableUs
Quetiapine Fumaratetablet50 mg/1oralCardinal Health2013-03-01Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralNorth Star Rx Llc2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralClinical Solutions Wholesale2012-03-28Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralAccord Healthcare Inc.2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralApotex Corp.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine Fumaratetablet400 mg/1oralREMEDYREPACK INC.2015-07-14Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralbryant ranch prepack2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralProficient Rx LP2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralAurobindo Pharma Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralAmerican Health Packaging2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralAvera Mc Kennan Hospital2015-07-29Not applicableUs
Quetiapine Fumaratetablet25 mg/1oralJubilant Cadista Pharmaceuticals Inc.2013-11-27Not applicableUs
Quetiapine Fumaratetablet200 mg/1oralRoxane Laboratories, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-07-17Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralSun Pharma Global FZE2012-03-28Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralUnit Dose Services2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralREMEDYREPACK INC.2013-09-26Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralDr.Reddy's Laboratories Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet50 mg/1oralTorrent Pharmaceuticals Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralCitron Pharma LLC2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralNorthstar Rx LLC2015-01-12Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralGolden State Medical Supply, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralREMEDYREPACK INC.2014-10-08Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralREMEDYREPACK INC.2013-02-08Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralREMEDYREPACK INC.2013-05-13Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralDr.Reddy's Laboratories Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralCardinal Health2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralNorthstar Rx LLC2015-01-12Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralClinical Solutions Wholesale2012-03-28Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralAv Kare, Inc.2014-01-17Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralApotex Corp.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralAlembic Pharmaceuticals Limited2012-03-26Not applicableUs
Quetiapine Fumaratetablet50 mg/1oralREMEDYREPACK INC.2015-12-24Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralTYA Pharmaceuticals2012-03-26Not applicableUs
Quetiapine Fumaratetablet400 mg/1oralAscend Laboratories, LLC2013-03-01Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralPreferred Pharmaceuticals, Inc.2014-04-23Not applicableUs
Quetiapine Fumaratetablet100 mg/1oralBlue Point Laboratories2013-02-28Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralMajor Pharmaceuticals2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralSun Pharma Global FZE2012-03-28Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralBreckenridge Pharmaceutical, Inc2012-03-26Not applicableUs
Quetiapine Fumaratetablet50 mg/1oralREMEDYREPACK INC.2014-07-09Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralCardinal Health2012-04-02Not applicableUs
Quetiapine Fumaratetablet400 mg/1oralTorrent Pharmaceuticals Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralCitron Pharma LLC2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralAccord Healthcare Inc.2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralApotex Corp.2012-03-27Not applicableUs
Quetiapine Fumaratetablet200 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralREMEDYREPACK INC.2015-03-12Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralbryant ranch prepack2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralAurobindo Pharma Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralAmerican Health Packaging2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralGolden State Medical Supply, Inc.2015-07-21Not applicableUs
Quetiapine Fumaratetablet200 mg/1oralLUPIN LIMITED2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralTeva Pharmaceuticals USA Inc2014-03-12Not applicableUs
Quetiapine Fumaratetablet150 mg/1oralSandoz Inc2013-04-05Not applicableUs
Quetiapine Fumaratetablet300 mg/1oralREMEDYREPACK INC.2015-07-16Not applicableUs
Quetiapine Fumaratetablet100 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2013-04-05Not applicableUs
Quetiapine Fumaratetablet150 mg/1oralAscend Laboratories, LLC2013-03-01Not applicableUs
Quetiapine Fumaratetablet200 mg/1oralLupin Pharmaceuticals, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet400 mg/1oralBlue Point Laboratories2013-02-28Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralTeva Pharmaceuticals USA Inc2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralMajor Pharmaceuticals2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralREMEDYREPACK INC.2013-02-07Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralREMEDYREPACK INC.2013-03-28Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralPhysicians Total Care, Inc.2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralCardinal Health2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralNorth Star Rx Llc2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralClinical Solutions Wholesale2012-03-28Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralAv Kare, Inc.2014-01-17Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralApotex Corp.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralAlembic Pharmaceuticals Limited2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralGolden State Medical Supply, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralREMEDYREPACK INC.2014-10-08Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralProficient Rx LP2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralAurobindo Pharma Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralAmerican Health Packaging2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Quetiapine Fumaratetablet25 mg/1oralLUPIN LIMITED2012-03-27Not applicableUs
Quetiapine Fumaratetablet300 mg/1oralRoxane Laboratories, Inc.2012-03-27Not applicableUs
Quetiapine Fumaratetablet50 mg/1oralSandoz Inc2013-04-05Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralSun Pharma Global FZE2012-03-28Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralUnit Dose Services2012-03-26Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralREMEDYREPACK INC.2014-04-14Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralDr.Reddy's Laboratories Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet100 mg/1oralTorrent Pharmaceuticals Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralCitron Pharma LLC2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralNorthstar Rx LLC2015-01-12Not applicableUs
Quetiapine Fumaratetablet, film coated400 mg/1oralMajor Pharmaceuticals2012-04-02Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralREMEDYREPACK INC.2013-02-15Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralREMEDYREPACK INC.2013-05-282016-04-05Us
Quetiapine Fumaratetablet, film coated150 mg/1oralDr.Reddy's Laboratories Limited2012-03-27Not applicableUs
Quetiapine Fumaratetablet200 mg/1oralCardinal Health2013-03-01Not applicableUs
Quetiapine Fumaratetablet, film coated50 mg/1oralNorthstar Rx LLC2015-01-12Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralClinical Solutions Wholesale2012-03-28Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralAv Kare, Inc.2014-01-17Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralApotex Corp.2012-03-27Not applicableUs
Quetiapine Fumaratetablet, film coated300 mg/1oralAlembic Pharmaceuticals Limited2012-03-26Not applicableUs
Quetiapine Fumaratetablet25 mg/1oralREMEDYREPACK INC.2015-12-24Not applicableUs
Quetiapine Fumaratetablet, film coated100 mg/1oralTYA Pharmaceuticals2012-03-26Not applicableUs
Quetiapine Fumaratetablet50 mg/1oralAscend Laboratories, LLC2013-03-01Not applicableUs
Quetiapine Fumaratetablet300 mg/1oralPreferred Pharmaceuticals, Inc.2014-03-31Not applicableUs
Quetiapine Fumaratetablet, film coated25 mg/1oralREMEDYREPACK INC.2016-01-20Not applicableUs
Quetiapine Fumaratetablet25 mg/1oralBlue Point Laboratories2013-02-28Not applicableUs
Quetiapine Fumaratetablet, film coated200 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIBGL0JSY5SI
CAS number111974-69-7
WeightAverage: 383.507
Monoisotopic: 383.166747749
Chemical FormulaC21H25N3O2S
InChI KeyInChIKey=URKOMYMAXPYINW-UHFFFAOYSA-N
InChI
InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
IUPAC Name
2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-10-yl}piperazin-1-yl)ethoxy]ethan-1-ol
SMILES
OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzothiazepines. These are compounds containing a dibenzothiazepine moiety, which consists of two benzene connected by a thiazepine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazepines
Sub ClassDibenzothiazepines
Direct ParentDibenzothiazepines
Alternative Parents
Substituents
  • Dibenzothiazepine
  • Diarylthioether
  • N-alkylpiperazine
  • Imidolactam
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Thioether
  • Ether
  • Dialkyl ether
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of schizophrenia and related psychotic disorders.
PharmacodynamicsQuetiapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Quetiapine is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), and dopamine type 2 (D2) receptors. Quetiapine is an antagonist at serotonin 5-HT1A and 5HT2, dopamine D1 and D2, histamine H1, and adrenergic alpha 1 and alpha 2 receptors. Quetiapine has no significant affinity for cholinergic muscarinic or benzodiazepine receptors. Drowsiness and orthostatic hypotension associated with use of quetiapine may be explained by its antagonism of histamine H1 and adrenergic alpha 1 receptors, respectively. Quetiapine's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.
Mechanism of actionQuetiapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.
Related Articles
AbsorptionRapidly and well absorbed.
Volume of distribution
  • 10±4 L/kg
Protein binding83%
Metabolism

Hepatic. The major metabolic pathways are sulfoxidation, mediated by cytochrome P450 3A4 (CYP3A4), and oxidation of the terminal alcohol to a carboxylic acid. The major sulfoxide metabolite of quetiapine is inactive. Quetiapine also undergoes hydroxylation of the dibenzothiazepine ring, O-deakylation, N-dealkylation, and phase II conjugation. The 7-hydroxy and 7-hydroxy- N-delakylated metabolites appear to be active, but are present in very low concentrations.

Route of eliminationElimination of quetiapine is mainly via hepatic metabolism. Following a single oral dose of 14C-quetiapine, less than 1% of the administered dose was excreted as unchanged drug, indicating that quetiapine is highly metabolized. Approximately 73% and 20% of the dose was recovered in the urine and feces, respectively.
Half life6 hours
ClearanceNot Available
ToxicitySymptoms of overdose include drowsiness and sedation, tachycardia, and hypotension.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9155
Blood Brain Barrier+0.9906
Caco-2 permeable-0.6037
P-glycoprotein substrateSubstrate0.8424
P-glycoprotein inhibitor IInhibitor0.9117
P-glycoprotein inhibitor IIInhibitor0.9325
Renal organic cation transporterInhibitor0.5554
CYP450 2C9 substrateNon-substrate0.6438
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6049
CYP450 1A2 substrateInhibitor0.5744
CYP450 2C9 inhibitorNon-inhibitor0.6305
CYP450 2D6 inhibitorInhibitor0.588
CYP450 2C19 inhibitorNon-inhibitor0.7033
CYP450 3A4 inhibitorInhibitor0.7961
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5375
Ames testNon AMES toxic0.7479
CarcinogenicityNon-carcinogens0.869
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6537 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9483
hERG inhibition (predictor II)Inhibitor0.8684
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet (immediate release)oral100 mg
Tablet (immediate release)oral200 mg
Tablet (immediate release)oral25 mg
Tablet (immediate release)oral300 mg
Tabletoral50 mg
Tabletoral100 mg/1
Tabletoral150 mg/1
Tabletoral200 mg/1
Tabletoral25 mg/1
Tabletoral300 mg/1
Tabletoral400 mg/1
Tabletoral50 mg/1
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral150 mg/1
Tablet, film coatedoral200 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral300 mg/1
Tablet, film coatedoral400 mg/1
Tablet, film coatedoral50 mg/1
Tabletoral300 mg
Tabletoral100 mg
Tabletoral200 mg
Tabletoral25 mg
Kit
Tablet (extended-release)oral150 mg
Tablet (extended-release)oral200 mg
Tablet (extended-release)oral300 mg
Tablet (extended-release)oral400 mg
Tablet (extended-release)oral50 mg
Tablet, extended releaseoral150 mg/1
Tablet, extended releaseoral200 mg/1
Tablet, extended releaseoral300 mg/1
Tablet, extended releaseoral400 mg/1
Tablet, extended releaseoral50 mg/1
Tabletoral150 mg
Prices
Unit descriptionCostUnit
Seroquel 400 mg tablet16.71USD tablet
Seroquel xr 400 mg tablet14.82USD tablet
Seroquel 300 mg tablet14.21USD tablet
Seroquel xr 300 mg tablet12.61USD tablet
Seroquel 200 mg tablet10.84USD tablet
SEROquel XR 200 mg 24 Hour tablet10.0USD tablet
Seroquel xr 200 mg tablet9.62USD tablet
SEROquel XR 150 mg 24 Hour tablet9.09USD tablet
Seroquel xr 150 mg tablet8.74USD tablet
Seroquel 100 mg tablet5.75USD tablet
Seroquel 50 mg tablet5.5USD tablet
SEROquel XR 50 mg 24 Hour tablet5.06USD tablet
Seroquel xr 50 mg tablet4.87USD tablet
Seroquel 300 mg Tablet4.35USD tablet
Seroquel 25 mg tablet3.35USD tablet
Seroquel 200 mg Tablet2.98USD tablet
Apo-Quetiapine 300 mg Tablet2.44USD tablet
Co Quetiapine 300 mg Tablet2.44USD tablet
Jamp-Quetiapine 300 mg Tablet2.44USD tablet
Mylan-Quetiapine 300 mg Tablet2.44USD tablet
Novo-Quetiapine 300 mg Tablet2.44USD tablet
Pms-Quetiapine 300 mg Tablet2.44USD tablet
Ratio-Quetiapine 300 mg Tablet2.44USD tablet
Sandoz Quetiapine 300 mg Tablet2.44USD tablet
Apo-Quetiapine 200 mg Tablet1.67USD tablet
Co Quetiapine 200 mg Tablet1.67USD tablet
Jamp-Quetiapine 200 mg Tablet1.67USD tablet
Mylan-Quetiapine 200 mg Tablet1.67USD tablet
Novo-Quetiapine 200 mg Tablet1.67USD tablet
Pms-Quetiapine 200 mg Tablet1.67USD tablet
Ratio-Quetiapine 200 mg Tablet1.67USD tablet
Sandoz Quetiapine 200 mg Tablet1.67USD tablet
Seroquel 100 mg Tablet1.48USD tablet
Novo-Quetiapine 150 mg Tablet1.42USD tablet
Apo-Quetiapine 100 mg Tablet0.83USD tablet
Co Quetiapine 100 mg Tablet0.83USD tablet
Jamp-Quetiapine 100 mg Tablet0.83USD tablet
Mylan-Quetiapine 100 mg Tablet0.83USD tablet
Novo-Quetiapine 100 mg Tablet0.83USD tablet
Pms-Quetiapine 100 mg Tablet0.83USD tablet
Ratio-Quetiapine 100 mg Tablet0.83USD tablet
Sandoz Quetiapine 100 mg Tablet0.83USD tablet
Seroquel 25 mg Tablet0.56USD tablet
Apo-Quetiapine 25 mg Tablet0.31USD tablet
Co Quetiapine 25 mg Tablet0.31USD tablet
Jamp-Quetiapine 25 mg Tablet0.31USD tablet
Mylan-Quetiapine 25 mg Tablet0.31USD tablet
Novo-Quetiapine 25 mg Tablet0.31USD tablet
Pms-Quetiapine 25 mg Tablet0.31USD tablet
Ratio-Quetiapine 25 mg Tablet0.31USD tablet
Sandoz Quetiapine 25 mg Tablet0.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2251944 No2007-04-102017-05-27Canada
US4879288 No1994-09-262011-09-26Us
US5948437 Yes1997-11-282017-11-28Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityModerateNot Available
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0403 mg/mLALOGPS
logP2.93ALOGPS
logP2.81ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)15.12ChemAxon
pKa (Strongest Basic)7.06ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area48.3 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity114.09 m3·mol-1ChemAxon
Polarizability42.78 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US4879288
General References
  1. Dev V, Raniwalla J: Quetiapine: a review of its safety in the management of schizophrenia. Drug Saf. 2000 Oct;23(4):295-307. [PubMed:11051217 ]
  2. Mukaddes NM, Abali O: Quetiapine treatment of children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol. 2003 Fall;13(3):295-9. [PubMed:14642017 ]
  3. Tallerico T, Novak G, Liu IS, Ulpian C, Seeman P: Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex. Brain Res Mol Brain Res. 2001 Mar 5;87(2):160-5. [PubMed:11245917 ]
  4. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
External Links
ATC CodesN05AH04
AHFS Codes
  • 28:16.08.04
PDB EntriesNot Available
FDA labelDownload (273 KB)
MSDSDownload (57.1 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineQuetiapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineQuetiapine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with 7-Nitroindazole.
AbirateroneThe metabolism of Quetiapine can be decreased when combined with Abiraterone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Quetiapine.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Quetiapine.
AcepromazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Quetiapine can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Quetiapine.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Quetiapine.
adipiplonThe risk or severity of adverse effects can be increased when Quetiapine is combined with adipiplon.
AfatinibThe serum concentration of Quetiapine can be increased when it is combined with Afatinib.
AgomelatineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Agomelatine.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Quetiapine.
AlbendazoleThe serum concentration of Quetiapine can be increased when it is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Quetiapine.
AldosteroneThe serum concentration of Quetiapine can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Quetiapine can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Alfaxalone.
AlfentanilThe serum concentration of Quetiapine can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Quetiapine.
AliskirenThe risk or severity of adverse effects can be increased when Quetiapine is combined with Aliskiren.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Quetiapine.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Quetiapine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Quetiapine.
AmantadineThe serum concentration of Quetiapine can be increased when it is combined with Amantadine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Quetiapine.
Aminohippuric acidThe serum concentration of Quetiapine can be increased when it is combined with Aminohippuric acid.
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Quetiapine.
AmisulprideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Quetiapine.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Quetiapine.
AmobarbitalAmobarbital may increase the hypotensive activities of Quetiapine.
AmobarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amperozide.
AmphetamineQuetiapine may decrease the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Quetiapine can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Quetiapine can be increased when it is combined with Amsacrine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amyl Nitrite.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Quetiapine.
ApomorphineApomorphine may increase the QTc-prolonging activities of Quetiapine.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Quetiapine.
AprepitantThe serum concentration of Quetiapine can be increased when it is combined with Aprepitant.
ArformoterolArformoterol may increase the QTc-prolonging activities of Quetiapine.
AripiprazoleAripiprazole may increase the hypotensive activities of Quetiapine.
AripiprazoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with Aripiprazole.
ArmodafinilThe metabolism of Quetiapine can be decreased when combined with Armodafinil.
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Quetiapine.
ArtemetherQuetiapine may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Articaine.
AsenapineQuetiapine may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe serum concentration of Quetiapine can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Quetiapine can be increased when it is combined with Atazanavir.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Quetiapine.
AtomoxetineThe metabolism of Quetiapine can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Quetiapine can be increased when it is combined with Atorvastatin.
AzaperoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Azaperone.
AzelastineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Quetiapine can be increased when it is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Azilsartan medoxomil.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Quetiapine.
BaclofenThe risk or severity of adverse effects can be increased when Quetiapine is combined with Baclofen.
BarbitalBarbital may increase the hypotensive activities of Quetiapine.
BarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Barbital.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Quetiapine.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Quetiapine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Quetiapine.
BenzocaineThe serum concentration of Quetiapine can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Benzocaine.
BenzphetamineQuetiapine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Quetiapine is combined with Benzyl alcohol.
BepridilThe serum concentration of Quetiapine can be increased when it is combined with Bepridil.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Quetiapine.
BexaroteneThe serum concentration of Quetiapine can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Quetiapine can be increased when it is combined with Biperiden.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Quetiapine.
BoceprevirThe serum concentration of Quetiapine can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Quetiapine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Quetiapine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Quetiapine can be increased when it is combined with Bosutinib.
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Quetiapine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.
BrimonidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Quetiapine.
BrompheniramineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brotizolam.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Quetiapine.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Quetiapine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Quetiapine.
BuprenorphineThe serum concentration of Quetiapine can be increased when it is combined with Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Buprenorphine.
BupropionThe metabolism of Quetiapine can be decreased when combined with Bupropion.
BuserelinBuserelin may increase the QTc-prolonging activities of Quetiapine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Quetiapine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Quetiapine.
ButacaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Quetiapine.
CabazitaxelThe serum concentration of Quetiapine can be increased when it is combined with Cabazitaxel.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Quetiapine.
CaffeineThe serum concentration of Quetiapine can be increased when it is combined with Caffeine.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quetiapine.
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Quetiapine.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Quetiapine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Quetiapine.
CarbamazepineThe serum concentration of Quetiapine can be decreased when it is combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carisoprodol.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Quetiapine.
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Quetiapine.
CaspofunginThe serum concentration of Quetiapine can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Quetiapine.
CelecoxibThe metabolism of Quetiapine can be decreased when combined with Celecoxib.
CeritinibCeritinib may increase the QTc-prolonging activities of Quetiapine.
CetirizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Quetiapine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Quetiapine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Quetiapine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Quetiapine.
ChloroquineChloroquine may increase the QTc-prolonging activities of Quetiapine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Quetiapine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorphenamine.
ChlorphentermineQuetiapine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Quetiapine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Quetiapine.
ChlorpropamideThe serum concentration of Quetiapine can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Quetiapine can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Quetiapine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Quetiapine can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Quetiapine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Quetiapine can be decreased when it is combined with Cholic Acid.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Quetiapine.
CilazaprilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cilazapril.
CimetidineThe serum concentration of Quetiapine can be decreased when it is combined with Cimetidine.
CinacalcetThe metabolism of Quetiapine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Quetiapine.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Quetiapine.
CisaprideCisapride may increase the QTc-prolonging activities of Quetiapine.
CitalopramCitalopram may increase the QTc-prolonging activities of Quetiapine.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Quetiapine.
ClemastineThe metabolism of Quetiapine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clidinium.
ClobazamThe metabolism of Quetiapine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clobazam.
ClofazimineThe serum concentration of Quetiapine can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Quetiapine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Quetiapine.
ClotrimazoleThe metabolism of Quetiapine can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Quetiapine.
ClozapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clozapine.
CobicistatThe serum concentration of Quetiapine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Quetiapine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Quetiapine.
ColchicineThe serum concentration of Quetiapine can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Quetiapine can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Quetiapine can be increased when it is combined with Conivaptan.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Quetiapine.
CyclizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quetiapine.
CyclophosphamideThe serum concentration of Quetiapine can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Quetiapine can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cyproheptadine.
DabrafenibThe serum concentration of Quetiapine can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Quetiapine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Quetiapine can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dantrolene.
DapagliflozinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Quetiapine.
DapoxetineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dapoxetine.
DarifenacinThe metabolism of Quetiapine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Quetiapine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Quetiapine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Quetiapine can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Quetiapine can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Quetiapine.
DelavirdineThe metabolism of Quetiapine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Quetiapine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Quetiapine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Quetiapine.
DesloratadineThe serum concentration of Quetiapine can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Quetiapine.
DetomidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Detomidine.
DexamethasoneThe serum concentration of Quetiapine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quetiapine.
DextroamphetamineQuetiapine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Quetiapine.
DextromoramideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Quetiapine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Quetiapine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Quetiapine.
DiclofenacThe serum concentration of Quetiapine can be increased when it is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Quetiapine.
DifenoxinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Difenoxin.
DigoxinThe serum concentration of Quetiapine can be decreased when it is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Quetiapine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydromorphine.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Quetiapine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dimenhydrinate.
DinutuximabThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dinutuximab.
DiphenhydramineThe metabolism of Quetiapine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Quetiapine.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Quetiapine.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Quetiapine.
DofetilideDofetilide may increase the QTc-prolonging activities of Quetiapine.
DolasetronDolasetron may increase the QTc-prolonging activities of Quetiapine.
DomperidoneDomperidone may increase the QTc-prolonging activities of Quetiapine.
DoramectinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Doramectin.
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Quetiapine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Quetiapine.
DoxorubicinThe serum concentration of Quetiapine can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Quetiapine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.
DoxylamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Quetiapine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.
DronedaroneQuetiapine may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Quetiapine.
DroperidolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Drotebanol.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Quetiapine.
DuloxetineQuetiapine may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Quetiapine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Quetiapine.
EcgonineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Quetiapine is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Quetiapine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Quetiapine is combined with Efavirenz.
ElbasvirThe serum concentration of Quetiapine can be increased when it is combined with Elbasvir.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Quetiapine.
EliglustatQuetiapine may increase the QTc-prolonging activities of Eliglustat.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Quetiapine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Quetiapine.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Quetiapine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Quetiapine.
EntacaponeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Entacapone.
EnzalutamideThe serum concentration of Quetiapine can be increased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Quetiapine.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Quetiapine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Quetiapine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Quetiapine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Quetiapine.
EribulinEribulin may increase the QTc-prolonging activities of Quetiapine.
ErythromycinErythromycin may increase the QTc-prolonging activities of Quetiapine.
EscitalopramEscitalopram may increase the QTc-prolonging activities of Quetiapine.
Eslicarbazepine acetateThe serum concentration of Quetiapine can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Quetiapine.
EsomeprazoleThe metabolism of Quetiapine can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Quetiapine.
EstramustineThe serum concentration of Quetiapine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Quetiapine can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Quetiapine can be decreased when it is combined with Estrone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Quetiapine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Quetiapine.
EthanolQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Quetiapine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Quetiapine.
EthosuximideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Quetiapine.
EtoperidoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etoperidone.
EtoposideThe serum concentration of Quetiapine can be increased when it is combined with Etoposide.
EtorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etorphine.
EtravirineThe serum concentration of Quetiapine can be decreased when it is combined with Etravirine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Quetiapine.
EzogabineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ezogabine.
FamotidineFamotidine may increase the QTc-prolonging activities of Quetiapine.
FelbamateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Felbamate.
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Quetiapine.
FencamfamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Quetiapine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quetiapine.
FexofenadineThe serum concentration of Quetiapine can be increased when it is combined with Fexofenadine.
FexofenadineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fexofenadine.
FidaxomicinThe serum concentration of Quetiapine can be increased when it is combined with Fidaxomicin.
FingolimodFingolimod may increase the QTc-prolonging activities of Quetiapine.
FlecainideFlecainide may increase the QTc-prolonging activities of Quetiapine.
FlibanserinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flibanserin.
FluconazoleThe metabolism of Quetiapine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flunitrazepam.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Quetiapine.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Quetiapine.
FluphenazineThe serum concentration of Quetiapine can be increased when it is combined with Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluphenazine.
FlurazepamThe serum concentration of Quetiapine can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Quetiapine.
FosamprenavirThe metabolism of Quetiapine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Quetiapine can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Quetiapine.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Quetiapine.
FosphenytoinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Quetiapine.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Quetiapine.
Fusidic AcidThe serum concentration of Quetiapine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Quetiapine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Quetiapine is combined with gabapentin enacarbil.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Quetiapine.
GalantamineGalantamine may increase the QTc-prolonging activities of Quetiapine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Quetiapine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Quetiapine can be increased when it is combined with Gefitinib.
GemfibrozilThe metabolism of Quetiapine can be decreased when combined with Gemfibrozil.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Quetiapine.
GenisteinThe serum concentration of Quetiapine can be increased when it is combined with Genistein.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Quetiapine.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Quetiapine.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Quetiapine.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Quetiapine.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Quetiapine.
GlutethimideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Glutethimide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Quetiapine.
GlyburideThe serum concentration of Quetiapine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Quetiapine can be increased when it is combined with Glycerol.
GoserelinGoserelin may increase the QTc-prolonging activities of Quetiapine.
Gramicidin DThe serum concentration of Quetiapine can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the QTc-prolonging activities of Quetiapine.
GrepafloxacinThe serum concentration of Quetiapine can be increased when it is combined with Grepafloxacin.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Quetiapine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Quetiapine.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Quetiapine.
HaloperidolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Quetiapine.
HeroinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Heroin.
HexobarbitalHexobarbital may increase the hypotensive activities of Quetiapine.
HexobarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Hexobarbital.
HistrelinHistrelin may increase the QTc-prolonging activities of Quetiapine.
HydralazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Quetiapine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Quetiapine.
HydrocortisoneThe serum concentration of Quetiapine can be increased when it is combined with Hydrocortisone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Quetiapine.
Hydroxyamphetamine hydrobromideQuetiapine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.
HydroxyzineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Hydroxyzine.
IbandronateIbandronate may increase the QTc-prolonging activities of Quetiapine.
IbutilideIbutilide may increase the QTc-prolonging activities of Quetiapine.
IdelalisibThe serum concentration of Quetiapine can be increased when it is combined with Idelalisib.
IloperidoneQuetiapine may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Quetiapine can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Quetiapine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Quetiapine.
IndalpineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Quetiapine.
IndinavirThe serum concentration of Quetiapine can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Quetiapine can be increased when it is combined with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Quetiapine.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Quetiapine.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Quetiapine.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Quetiapine.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Quetiapine.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Quetiapine.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Quetiapine.
IsavuconazoniumThe metabolism of Quetiapine can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Quetiapine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Quetiapine.
IsoniazidThe metabolism of Quetiapine can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Quetiapine.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Quetiapine.
IsoxsuprineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Quetiapine.
ItraconazoleThe serum concentration of Quetiapine can be increased when it is combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Quetiapine.
IvacaftorThe serum concentration of Quetiapine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Quetiapine can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Quetiapine can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ketobemidone.
KetoconazoleThe serum concentration of Quetiapine can be increased when it is combined with Ketoconazole.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Quetiapine.
LamotrigineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lamotrigine.
LansoprazoleThe serum concentration of Quetiapine can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Quetiapine can be increased when it is combined with Lapatinib.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Quetiapine.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Quetiapine.
LevetiracetamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levetiracetam.
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Quetiapine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Quetiapine.
LevocabastineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levocetirizine.
LevodopaQuetiapine may increase the orthostatic hypotensive activities of Levodopa.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Quetiapine.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Quetiapine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Quetiapine.
LevothyroxineThe serum concentration of Quetiapine can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Quetiapine can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Quetiapine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Quetiapine.
LiothyronineThe serum concentration of Quetiapine can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Quetiapine can be decreased when it is combined with Liotrix.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Quetiapine.
LisdexamfetamineQuetiapine may decrease the stimulatory activities of Lisdexamfetamine.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Quetiapine.
LithiumLithium may increase the neurotoxic activities of Quetiapine.
LithiumThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lofentanil.
LomitapideThe serum concentration of Quetiapine can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Quetiapine can be increased when it is combined with Loperamide.
LopinavirQuetiapine may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe serum concentration of Quetiapine can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Quetiapine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Quetiapine.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Quetiapine.
LovastatinThe metabolism of Quetiapine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Quetiapine.
Lu AA21004The risk or severity of adverse effects can be increased when Quetiapine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Quetiapine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Quetiapine can be decreased when it is combined with Lumacaftor.
LumefantrineQuetiapine may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Quetiapine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Quetiapine.
MebendazoleThe serum concentration of Quetiapine can be increased when it is combined with Mebendazole.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quetiapine.
MeclizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Medetomidine.
MefloquineThe serum concentration of Quetiapine can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Quetiapine can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Quetiapine.
MelperoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Melperone.
MephentermineQuetiapine may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Quetiapine.
MeprobamateThe serum concentration of Quetiapine can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Meprobamate.
MequitazineQuetiapine may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Quetiapine.
MetaxaloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Metaxalone.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Quetiapine.
MethadoneMethadone may increase the QTc-prolonging activities of Quetiapine.
MethadoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methadyl Acetate.
MethamphetamineQuetiapine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Quetiapine.
MethocarbamolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methocarbamol.
MethohexitalMethohexital may increase the hypotensive activities of Quetiapine.
MethohexitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Quetiapine.
MethsuximideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Quetiapine.
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Quetiapine.
MethylphenidateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenidate.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Quetiapine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenobarbital.
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Quetiapine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Quetiapine.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Quetiapine.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Quetiapine.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Quetiapine.
MetyrosineQuetiapine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Quetiapine.
MibefradilThe serum concentration of Quetiapine can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Quetiapine can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Quetiapine can be decreased when it is combined with Midazolam.
MidazolamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Midazolam.
MifepristoneMifepristone may increase the QTc-prolonging activities of Quetiapine.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Quetiapine.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Quetiapine.
MilnacipranThe risk or severity of adverse effects can be increased when Quetiapine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Quetiapine.
MirabegronThe metabolism of Quetiapine can be decreased when combined with Mirabegron.
MirtazapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Quetiapine.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Quetiapine.
MitomycinThe serum concentration of Quetiapine can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Quetiapine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Quetiapine can be decreased when it is combined with Mitoxantrone.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Quetiapine.
ModafinilThe serum concentration of Quetiapine can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Quetiapine.
MolindoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Molindone.
MorphineThe serum concentration of Quetiapine can be increased when it is combined with Morphine.
MorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Morphine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Quetiapine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.
NabiloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nabilone.
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Quetiapine.
NafcillinThe serum concentration of Quetiapine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Quetiapine.
NaltrexoneThe serum concentration of Quetiapine can be increased when it is combined with Naltrexone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Quetiapine.
NaringeninThe serum concentration of Quetiapine can be increased when it is combined with Naringenin.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Quetiapine.
NebivololThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nebivolol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Quetiapine.
NelfinavirThe serum concentration of Quetiapine can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Quetiapine can be increased when it is combined with Neostigmine.
NesiritideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nesiritide.
NetupitantThe serum concentration of Quetiapine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Quetiapine can be decreased when combined with Nevirapine.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Quetiapine.
NicorandilNicorandil may increase the hypotensive activities of Quetiapine.
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Quetiapine.
NilotinibQuetiapine may increase the QTc-prolonging activities of Nilotinib.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Quetiapine.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Quetiapine.
NitrazepamThe serum concentration of Quetiapine can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nitrazepam.
NitrendipineThe serum concentration of Quetiapine can be increased when it is combined with Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Quetiapine.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Quetiapine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nitrous oxide.
NorethisteroneThe serum concentration of Quetiapine can be decreased when it is combined with Norethisterone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Quetiapine.
NormethadoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Quetiapine.
OctreotideOctreotide may increase the QTc-prolonging activities of Quetiapine.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Quetiapine.
OlanzapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Olanzapine.
OlaparibThe metabolism of Quetiapine can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Quetiapine.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Quetiapine.
OlopatadineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Olopatadine.
OmeprazoleThe serum concentration of Quetiapine can be increased when it is combined with Omeprazole.
OndansetronOndansetron may increase the QTc-prolonging activities of Quetiapine.
OndansetronThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Quetiapine is combined with Opium.
OrphenadrineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Quetiapine.
OsanetantThe risk or severity of adverse effects can be increased when Quetiapine is combined with Osanetant.
OsimertinibThe serum concentration of Quetiapine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Quetiapine.
OxprenololThe risk or severity of adverse effects can be increased when Quetiapine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Quetiapine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quetiapine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Quetiapine.
OxytocinOxytocin may increase the QTc-prolonging activities of Quetiapine.
P-NitrophenolThe serum concentration of Quetiapine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Quetiapine can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Quetiapine can be increased when it is combined with Palbociclib.
PaliperidoneQuetiapine may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Quetiapine can be increased when it is combined with Palmitic Acid.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Quetiapine.
PantoprazoleThe serum concentration of Quetiapine can be increased when it is combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Quetiapine.
ParaldehydeQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Quetiapine.
ParoxetineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Quetiapine.
PazopanibPazopanib may increase the QTc-prolonging activities of Quetiapine.
Peginterferon alfa-2bThe serum concentration of Quetiapine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololThe risk or severity of adverse effects can be increased when Quetiapine is combined with Penbutolol.
PentamidinePentamidine may increase the QTc-prolonging activities of Quetiapine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quetiapine.
PentobarbitalPentobarbital may increase the hypotensive activities of Quetiapine.
PentobarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pentobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Quetiapine is combined with Perampanel.
PerflutrenPerflutren may increase the QTc-prolonging activities of Quetiapine.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Quetiapine.
PerospironeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Quetiapine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Quetiapine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Quetiapine.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Quetiapine.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Quetiapine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phenoxyethanol.
PhentermineQuetiapine may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phenytoin.
PimozidePimozide may increase the QTc-prolonging activities of Quetiapine.
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Quetiapine.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Quetiapine.
PipamperoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Quetiapine can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pomalidomide.
PonatinibThe serum concentration of Quetiapine can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Quetiapine can be increased when it is combined with Posaconazole.
PramipexoleQuetiapine may increase the sedative activities of Pramipexole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Quetiapine.
PramocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pramocaine.
PravastatinThe serum concentration of Quetiapine can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Prazepam.
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Quetiapine.
PrednisoneThe serum concentration of Quetiapine can be increased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Quetiapine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Quetiapine.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Quetiapine.
PrimidonePrimidone may increase the hypotensive activities of Quetiapine.
PrimidoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Primidone.
ProbenecidThe serum concentration of Quetiapine can be increased when it is combined with Probenecid.
ProcainamideProcainamide may increase the QTc-prolonging activities of Quetiapine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Quetiapine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Quetiapine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quetiapine.
ProgesteroneThe serum concentration of Quetiapine can be decreased when it is combined with Progesterone.
PromazinePromazine may increase the QTc-prolonging activities of Quetiapine.
PromazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Quetiapine.
PropafenonePropafenone may increase the QTc-prolonging activities of Quetiapine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Quetiapine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Quetiapine.
PropoxycaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Propoxycaine.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Quetiapine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Quetiapine.
PSD502The risk or severity of adverse effects can be increased when Quetiapine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Quazepam.
QuercetinThe serum concentration of Quetiapine can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Quetiapine can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Quetiapine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Quetiapine.
QuinidineQuinidine may increase the QTc-prolonging activities of Quetiapine.
QuinineQuinine may increase the QTc-prolonging activities of Quetiapine.
RamelteonThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ramelteon.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Quetiapine.
RanitidineThe serum concentration of Quetiapine can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Quetiapine can be increased when it is combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Quetiapine.
ReboxetineThe serum concentration of Quetiapine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Quetiapine can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quetiapine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Quetiapine.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Quetiapine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quetiapine.
RifabutinThe serum concentration of Quetiapine can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Quetiapine can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Quetiapine can be decreased when it is combined with Rifapentine.
RilpivirineThe serum concentration of Quetiapine can be increased when it is combined with Rilpivirine.
RiociguatThe risk or severity of adverse effects can be increased when Quetiapine is combined with Riociguat.
RisperidoneQuetiapine may increase the hypotensive activities of Risperidone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Quetiapine.
RitonavirThe serum concentration of Quetiapine can be decreased when it is combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Quetiapine.
RolapitantThe serum concentration of Quetiapine can be increased when it is combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Romifidine.
RopiniroleQuetiapine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Quetiapine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Quetiapine.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Quetiapine.
RotigotineQuetiapine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Quetiapine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Quetiapine is combined with S-Ethylisothiourea.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Quetiapine.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Quetiapine.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Quetiapine.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Quetiapine.
ScopolamineThe serum concentration of Quetiapine can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Quetiapine.
SecobarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Secobarbital.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Quetiapine.
SertindoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sevoflurane.
SildenafilThe metabolism of Quetiapine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Quetiapine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Quetiapine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Quetiapine can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Quetiapine can be decreased when it is combined with Sirolimus.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Quetiapine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sodium oxybate.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Quetiapine.
SorafenibThe serum concentration of Quetiapine can be increased when it is combined with Sorafenib.
SotalolSotalol may increase the QTc-prolonging activities of Quetiapine.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Quetiapine.
St. John's WortQuetiapine may increase the serotonergic activities of St. John's Wort.
St. John's WortThe serum concentration of Quetiapine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Quetiapine can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Stiripentol.
StreptozocinThe serum concentration of Quetiapine can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quetiapine.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Quetiapine.
SulfinpyrazoneThe serum concentration of Quetiapine can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Quetiapine.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Quetiapine.
SulpirideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Quetiapine.
SunitinibThe serum concentration of Quetiapine can be increased when it is combined with Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Quetiapine is combined with Suvorexant.
TacrineThe serum concentration of Quetiapine can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Quetiapine can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Quetiapine can be decreased when it is combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Quetiapine.
TasimelteonThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Quetiapine can be increased when it is combined with Taurocholic Acid.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Quetiapine.
TelaprevirThe serum concentration of Quetiapine can be increased when it is combined with Telaprevir.
TelavancinTelavancin may increase the QTc-prolonging activities of Quetiapine.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Quetiapine.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Quetiapine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Quetiapine.
TemsirolimusThe serum concentration of Quetiapine can be increased when it is combined with Temsirolimus.
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Quetiapine.
TerbinafineThe metabolism of Quetiapine can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Quetiapine.
TerfenadineThe serum concentration of Quetiapine can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Quetiapine can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Quetiapine can be increased when it is combined with Testosterone.
TetrabenazineQuetiapine may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tetrodotoxin.
ThalidomideQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Quetiapine.
ThiamylalThiamylal may increase the hypotensive activities of Quetiapine.
ThiamylalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Thiamylal.
ThiopentalThiopental may increase the hypotensive activities of Quetiapine.
ThiopentalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Thiopental.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Quetiapine.
ThioridazineThioridazine may increase the QTc-prolonging activities of Quetiapine.
ThiothixeneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tiagabine.
TicagrelorThe serum concentration of Quetiapine can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Quetiapine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tiletamine.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Quetiapine.
TipranavirThe metabolism of Quetiapine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Quetiapine.
TocilizumabThe serum concentration of Quetiapine can be decreased when it is combined with Tocilizumab.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Quetiapine.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Quetiapine.
TolcaponeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tolcapone.
TolterodineTolterodine may increase the QTc-prolonging activities of Quetiapine.
TolvaptanThe serum concentration of Quetiapine can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Quetiapine.
ToremifeneToremifene may increase the QTc-prolonging activities of Quetiapine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Quetiapine.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Quetiapine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Quetiapine.
TrazodoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Quetiapine.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Quetiapine.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Quetiapine.
TrifluoperazineThe serum concentration of Quetiapine can be increased when it is combined with Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Quetiapine can be increased when it is combined with Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Triflupromazine.
TrimethoprimThe serum concentration of Quetiapine can be decreased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Quetiapine.
TriprolidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Triprolidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Quetiapine.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Quetiapine.
TroleandomycinThe serum concentration of Quetiapine can be increased when it is combined with Troleandomycin.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Quetiapine.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Quetiapine.
VandetanibQuetiapine may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Quetiapine.
VemurafenibQuetiapine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Quetiapine.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Quetiapine.
VigabatrinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Vigabatrin.
VilanterolVilanterol may increase the QTc-prolonging activities of Quetiapine.
VilazodoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Vilazodone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Quetiapine.
VinblastineThe serum concentration of Quetiapine can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Quetiapine can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Quetiapine can be increased when it is combined with Vinorelbine.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Quetiapine.
VoriconazoleThe metabolism of Quetiapine can be decreased when combined with Voriconazole.
VorinostatVorinostat may increase the QTc-prolonging activities of Quetiapine.
VortioxetineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Quetiapine.
ZiconotideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zimelidine.
ZimelidineThe serum concentration of Quetiapine can be increased when it is combined with Zimelidine.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Quetiapine.
ZolazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Quetiapine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Quetiapine.
ZonisamideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Quetiapine.
ZotepineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zotepine.
ZuclopenthixolQuetiapine may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Goldstein JM: Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today (Barc). 1999 Mar;35(3):193-210. [PubMed:12973385 ]
  2. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ: A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother. 2007 Jun;8(9):1211-9. [PubMed:17563257 ]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  4. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, Suppes T, Calabrese JR: Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66 Suppl 5:40-8. [PubMed:16038601 ]
  5. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P: A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000 Jun;57(6):553-9. [PubMed:10839333 ]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  3. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  4. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Ichikawa J, Li Z, Dai J, Meltzer HY: Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002 Nov 29;956(2):349-57. [PubMed:12445705 ]
  2. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ: A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother. 2007 Jun;8(9):1211-9. [PubMed:17563257 ]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  4. Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN: Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52. [PubMed:16918396 ]
  5. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
  2. DeVane CL, Nemeroff CB: Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40(7):509-22. [PubMed:11510628 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 03:38